Detailed price information for Novavax Inc (NVAX-Q) from The Globe and Mail including charting and trades.
Oppenheimer upgrades Incyte, citing growth beyond Jakafi exclusivity loss, strong Opzelura sales, and pipeline upside. Read more here.
Incyte (NASDAQ:INCY) reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in Jakafi sales. The company also raised its full-year sales outlook for OPZELURA, hematology and oncol
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 14% year on year to $1.56 billion. On the other hand, the company’s full-year revenue guidance of $5.26 billion at the midpoint came in 11.3% below analysts’ consensus estimates. Its non-GAAP loss of $3.60 per share was 6.9% above analysts’ consensus estimates.
Incyte (INCY) delivered earnings and revenue surprises of +9.77% and +5.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.